MN 576 Unit 10 Advanced Nursing Practice Study Guide,
Comprehensive Exam Review Notes, Graduate Nursing
Assignment Help Resource, Evidence-Based Clinical
Decision-Making Manual for Psychiatric and Mental Health
Nursing Success
Question 1: A 52-year-old woman presents with irregular menstrual cycles, night sweats, and
sleep disturbance for the past 8 months. Her last menstrual period was 6 weeks ago. She has
no history of thromboembolic disease, breast cancer, or unexplained vaginal bleeding.
According to current clinical guidelines, which intervention is most appropriate as first-line
management for her vasomotor symptoms?
A. Initiate combined estrogen-progestin hormone therapy immediately
B. Recommend non-hormonal options such as SSRIs or gabapentin as first-line
C. Schedule endometrial biopsy before considering any treatment
D. Advise lifestyle modifications alone with no pharmacologic intervention
CORRECT ANSWER: B. Recommend non-hormonal options such as SSRIs or gabapentin as
first-line
Rationale: Current guidelines from The North American Menopause Society (NAMS) and ACOG
recommend that for women with contraindications to hormone therapy or who prefer non-
hormonal approaches, selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), or gabapentin are appropriate first-line
pharmacologic options for managing vasomotor symptoms. While hormone therapy remains
the most effective treatment, shared decision-making and consideration of non-hormonal
alternatives are essential, especially when evaluating risk-benefit profiles. Endometrial biopsy is
not routinely indicated without abnormal uterine bleeding, and lifestyle modifications alone
may be insufficient for moderate-to-severe symptoms.
Question 2: Which statement regarding cervical cancer screening guidelines for average-risk
women is CORRECT according to the 2020 ACS and USPSTF recommendations?
A. Screening should begin at age 18 with annual Pap testing
B. Primary HPV testing alone every 5 years is preferred for women ages 30-65
C. Co-testing (Pap and HPV) every 3 years is recommended for women ages 21-29
D. Screening can be discontinued at age 55 regardless of prior screening history
CORRECT ANSWER: B. Primary HPV testing alone every 5 years is preferred for women ages
30-65
Rationale: The 2020 American Cancer Society (ACS) guidelines prefer primary HPV testing every
5 years for average-risk women ages 30-65. If primary HPV testing is unavailable, co-testing
(cytology plus HPV testing) every 5 years or cytology alone every 3 years are acceptable
alternatives. Screening begins at age 25 (not 18) per ACS, and USPSTF recommends starting at
21. For women ages 21-29, cytology alone every 3 years is recommended; co-testing is not
advised in this age group due to high HPV prevalence and low cancer risk. Screening may be
discontinued after age 65 with adequate prior negative screening and no high-risk history, not
at age 55.
,MN 576 Unit 10 Advanced Nursing Practice Study Guide,
Comprehensive Exam Review Notes, Graduate Nursing
Assignment Help Resource, Evidence-Based Clinical
Decision-Making Manual for Psychiatric and Mental Health
Nursing Success
Question 3: A 28-year-old woman requests contraception. She has migraines with aura,
smokes 10 cigarettes daily, and has a BMI of 32. Which contraceptive method is
CONTRAINDICATED for this patient?
A. Levonorgestrel intrauterine device (IUD)
B. Combined oral contraceptive pills containing estrogen
C. Depot medroxyprogesterone acetate injection
D. Etonogestrel subdermal implant
CORRECT ANSWER: B. Combined oral contraceptive pills containing estrogen
Rationale: Combined hormonal contraceptives (containing estrogen) are contraindicated in
women who smoke and are over age 35, but also carry increased stroke risk in women with
migraines with aura regardless of age or smoking status. The CDC Medical Eligibility Criteria
classify migraines with aura as Category 4 (unacceptable health risk) for combined hormonal
methods. Progestin-only methods (IUD, implant, injection) and non-hormonal options are safe
and preferred. This patient's smoking and BMI further elevate cardiovascular risk, reinforcing
avoidance of estrogen-containing products.
Question 4: During a well-woman exam, a 45-year-old patient asks about breast cancer
screening. She has no family history of breast or ovarian cancer and no known genetic
mutations. According to USPSTF 2023 draft recommendations, what is the recommended
screening strategy?
A. Annual mammography starting at age 40
B. Biennial mammography starting at age 40
C. Annual MRI plus mammography starting at age 45
D. Clinical breast exam every 6 months with mammography at age 50
CORRECT ANSWER: B. Biennial mammography starting at age 40
Rationale: The 2023 USPSTF draft recommendation (finalized in 2024) advises biennial
screening mammography for average-risk women starting at age 40 and continuing through
age 74. This represents a change from prior guidance that started at age 50. Annual screening is
not universally recommended due to increased false positives and overdiagnosis without clear
mortality benefit. MRI screening is reserved for high-risk women (e.g., BRCA carriers, strong
family history, prior chest radiation). Clinical breast exam alone is not recommended as a
primary screening modality per USPSTF due to insufficient evidence of benefit.
Question 5: A 34-year-old woman presents with heavy menstrual bleeding (HMB) lasting 8
days per cycle, requiring pad changes every 1-2 hours. She desires future fertility. Pelvic exam
and ultrasound are unremarkable. Which is the most appropriate initial pharmacologic
management?
, MN 576 Unit 10 Advanced Nursing Practice Study Guide,
Comprehensive Exam Review Notes, Graduate Nursing
Assignment Help Resource, Evidence-Based Clinical
Decision-Making Manual for Psychiatric and Mental Health
Nursing Success
A. Hysterectomy
B. Levonorgestrel-releasing intrauterine system (LNG-IUD)
C. Combined oral contraceptives
D. Tranexamic acid taken only during menses
CORRECT ANSWER: B. Levonorgestrel-releasing intrauterine system (LNG-IUD)
Rationale: For women with heavy menstrual bleeding who desire future fertility and have no
structural pathology, the levonorgestrel-releasing IUD (Mirena, Liletta) is recommended as first-
line pharmacologic therapy by ACOG. It significantly reduces menstrual blood loss (by 70-90%),
provides highly effective contraception, and is reversible. Tranexamic acid is an option for acute
management but is less effective long-term and requires dosing only during menses. Combined
oral contraceptives can help regulate cycles but are less effective than LNG-IUD for reducing
heavy bleeding. Hysterectomy is definitive but not appropriate as initial management for a
patient desiring fertility.
Question 6: Which finding in a postmenopausal woman warrants immediate evaluation for
endometrial cancer?
A. Occasional hot flashes without sleep disturbance
B. Vaginal dryness causing dyspareunia
C. Any episode of postmenopausal bleeding
D. Mild urinary urgency without infection
CORRECT ANSWER: C. Any episode of postmenopausal bleeding
Rationale: Postmenopausal bleeding (any vaginal bleeding occurring ≥12 months after final
menstrual period) is the presenting symptom in over 90% of endometrial cancer cases and
requires prompt evaluation regardless of volume or frequency. Guidelines mandate
transvaginal ultrasound to assess endometrial thickness and/or endometrial biopsy for all
women with postmenopausal bleeding. While hot flashes, vaginal atrophy, and urinary
symptoms are common menopausal complaints, they are not red flags for malignancy. Failure
to evaluate postmenopausal bleeding can delay diagnosis of endometrial hyperplasia or cancer.
Question 7: A 24-year-old woman presents for preconception counseling. She has no chronic
medical conditions, takes no medications, and has a BMI of 24. Which intervention is MOST
critical to initiate before conception?
A. Start prenatal vitamin with 400 mcg folic acid daily
B. Obtain baseline TSH and HbA1c screening
C. Schedule first-trimester ultrasound dating
D. Begin low-dose aspirin for preeclampsia prevention
CORRECT ANSWER: A. Start prenatal vitamin with 400 mcg folic acid daily
Comprehensive Exam Review Notes, Graduate Nursing
Assignment Help Resource, Evidence-Based Clinical
Decision-Making Manual for Psychiatric and Mental Health
Nursing Success
Question 1: A 52-year-old woman presents with irregular menstrual cycles, night sweats, and
sleep disturbance for the past 8 months. Her last menstrual period was 6 weeks ago. She has
no history of thromboembolic disease, breast cancer, or unexplained vaginal bleeding.
According to current clinical guidelines, which intervention is most appropriate as first-line
management for her vasomotor symptoms?
A. Initiate combined estrogen-progestin hormone therapy immediately
B. Recommend non-hormonal options such as SSRIs or gabapentin as first-line
C. Schedule endometrial biopsy before considering any treatment
D. Advise lifestyle modifications alone with no pharmacologic intervention
CORRECT ANSWER: B. Recommend non-hormonal options such as SSRIs or gabapentin as
first-line
Rationale: Current guidelines from The North American Menopause Society (NAMS) and ACOG
recommend that for women with contraindications to hormone therapy or who prefer non-
hormonal approaches, selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), or gabapentin are appropriate first-line
pharmacologic options for managing vasomotor symptoms. While hormone therapy remains
the most effective treatment, shared decision-making and consideration of non-hormonal
alternatives are essential, especially when evaluating risk-benefit profiles. Endometrial biopsy is
not routinely indicated without abnormal uterine bleeding, and lifestyle modifications alone
may be insufficient for moderate-to-severe symptoms.
Question 2: Which statement regarding cervical cancer screening guidelines for average-risk
women is CORRECT according to the 2020 ACS and USPSTF recommendations?
A. Screening should begin at age 18 with annual Pap testing
B. Primary HPV testing alone every 5 years is preferred for women ages 30-65
C. Co-testing (Pap and HPV) every 3 years is recommended for women ages 21-29
D. Screening can be discontinued at age 55 regardless of prior screening history
CORRECT ANSWER: B. Primary HPV testing alone every 5 years is preferred for women ages
30-65
Rationale: The 2020 American Cancer Society (ACS) guidelines prefer primary HPV testing every
5 years for average-risk women ages 30-65. If primary HPV testing is unavailable, co-testing
(cytology plus HPV testing) every 5 years or cytology alone every 3 years are acceptable
alternatives. Screening begins at age 25 (not 18) per ACS, and USPSTF recommends starting at
21. For women ages 21-29, cytology alone every 3 years is recommended; co-testing is not
advised in this age group due to high HPV prevalence and low cancer risk. Screening may be
discontinued after age 65 with adequate prior negative screening and no high-risk history, not
at age 55.
,MN 576 Unit 10 Advanced Nursing Practice Study Guide,
Comprehensive Exam Review Notes, Graduate Nursing
Assignment Help Resource, Evidence-Based Clinical
Decision-Making Manual for Psychiatric and Mental Health
Nursing Success
Question 3: A 28-year-old woman requests contraception. She has migraines with aura,
smokes 10 cigarettes daily, and has a BMI of 32. Which contraceptive method is
CONTRAINDICATED for this patient?
A. Levonorgestrel intrauterine device (IUD)
B. Combined oral contraceptive pills containing estrogen
C. Depot medroxyprogesterone acetate injection
D. Etonogestrel subdermal implant
CORRECT ANSWER: B. Combined oral contraceptive pills containing estrogen
Rationale: Combined hormonal contraceptives (containing estrogen) are contraindicated in
women who smoke and are over age 35, but also carry increased stroke risk in women with
migraines with aura regardless of age or smoking status. The CDC Medical Eligibility Criteria
classify migraines with aura as Category 4 (unacceptable health risk) for combined hormonal
methods. Progestin-only methods (IUD, implant, injection) and non-hormonal options are safe
and preferred. This patient's smoking and BMI further elevate cardiovascular risk, reinforcing
avoidance of estrogen-containing products.
Question 4: During a well-woman exam, a 45-year-old patient asks about breast cancer
screening. She has no family history of breast or ovarian cancer and no known genetic
mutations. According to USPSTF 2023 draft recommendations, what is the recommended
screening strategy?
A. Annual mammography starting at age 40
B. Biennial mammography starting at age 40
C. Annual MRI plus mammography starting at age 45
D. Clinical breast exam every 6 months with mammography at age 50
CORRECT ANSWER: B. Biennial mammography starting at age 40
Rationale: The 2023 USPSTF draft recommendation (finalized in 2024) advises biennial
screening mammography for average-risk women starting at age 40 and continuing through
age 74. This represents a change from prior guidance that started at age 50. Annual screening is
not universally recommended due to increased false positives and overdiagnosis without clear
mortality benefit. MRI screening is reserved for high-risk women (e.g., BRCA carriers, strong
family history, prior chest radiation). Clinical breast exam alone is not recommended as a
primary screening modality per USPSTF due to insufficient evidence of benefit.
Question 5: A 34-year-old woman presents with heavy menstrual bleeding (HMB) lasting 8
days per cycle, requiring pad changes every 1-2 hours. She desires future fertility. Pelvic exam
and ultrasound are unremarkable. Which is the most appropriate initial pharmacologic
management?
, MN 576 Unit 10 Advanced Nursing Practice Study Guide,
Comprehensive Exam Review Notes, Graduate Nursing
Assignment Help Resource, Evidence-Based Clinical
Decision-Making Manual for Psychiatric and Mental Health
Nursing Success
A. Hysterectomy
B. Levonorgestrel-releasing intrauterine system (LNG-IUD)
C. Combined oral contraceptives
D. Tranexamic acid taken only during menses
CORRECT ANSWER: B. Levonorgestrel-releasing intrauterine system (LNG-IUD)
Rationale: For women with heavy menstrual bleeding who desire future fertility and have no
structural pathology, the levonorgestrel-releasing IUD (Mirena, Liletta) is recommended as first-
line pharmacologic therapy by ACOG. It significantly reduces menstrual blood loss (by 70-90%),
provides highly effective contraception, and is reversible. Tranexamic acid is an option for acute
management but is less effective long-term and requires dosing only during menses. Combined
oral contraceptives can help regulate cycles but are less effective than LNG-IUD for reducing
heavy bleeding. Hysterectomy is definitive but not appropriate as initial management for a
patient desiring fertility.
Question 6: Which finding in a postmenopausal woman warrants immediate evaluation for
endometrial cancer?
A. Occasional hot flashes without sleep disturbance
B. Vaginal dryness causing dyspareunia
C. Any episode of postmenopausal bleeding
D. Mild urinary urgency without infection
CORRECT ANSWER: C. Any episode of postmenopausal bleeding
Rationale: Postmenopausal bleeding (any vaginal bleeding occurring ≥12 months after final
menstrual period) is the presenting symptom in over 90% of endometrial cancer cases and
requires prompt evaluation regardless of volume or frequency. Guidelines mandate
transvaginal ultrasound to assess endometrial thickness and/or endometrial biopsy for all
women with postmenopausal bleeding. While hot flashes, vaginal atrophy, and urinary
symptoms are common menopausal complaints, they are not red flags for malignancy. Failure
to evaluate postmenopausal bleeding can delay diagnosis of endometrial hyperplasia or cancer.
Question 7: A 24-year-old woman presents for preconception counseling. She has no chronic
medical conditions, takes no medications, and has a BMI of 24. Which intervention is MOST
critical to initiate before conception?
A. Start prenatal vitamin with 400 mcg folic acid daily
B. Obtain baseline TSH and HbA1c screening
C. Schedule first-trimester ultrasound dating
D. Begin low-dose aspirin for preeclampsia prevention
CORRECT ANSWER: A. Start prenatal vitamin with 400 mcg folic acid daily
